OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY.

Annals of the rheumatic diseases
2020
https://researcherprofiles.org/profile/171380718
D. Van der Heijde, L. S. Gensler, A. Deodhar, X. Baraliakos, D. Poddubnyy, A. Kivitz, M. K. Farmer, D. Baeten, N. Goldammer, J. Coarse, M. Oortgiesen, M. Dougados